Figure 4.
PAC/SIR/TAC maintains T, B, and NK cell engraftment. (A) Number of CD3+ T cells pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (B-D) Number of CD3+ (B), CD4+ (C), and CD8+ (D) T cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs recommended phase 2 dose (RP2D) PAC/SIR/TAC. (E) Number of CD19+ B cells pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (F) Number of CD19+ B cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. (G) Number of CD16+, CD56+ NK cells pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (H) Number of CD16+, CD56+ NK cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. ∗P < .05 and ∗∗∗P = .001-.0001. NS, not significant.

PAC/SIR/TAC maintains T, B, and NK cell engraftment. (A) Number of CD3+ T cells pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (B-D) Number of CD3+ (B), CD4+ (C), and CD8+ (D) T cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs recommended phase 2 dose (RP2D) PAC/SIR/TAC. (E) Number of CD19+ B cells pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (F) Number of CD19+ B cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. (G) Number of CD16+, CD56+ NK cells pretransplant and at days +21 and +100 among patients treated on phase 2 PAC/SIR/TAC. (H) Number of CD16+, CD56+ NK cells at day +21 among patients treated with dose level 1 PAC/SIR/TAC vs RP2D PAC/SIR/TAC. ∗P < .05 and ∗∗∗P = .001-.0001. NS, not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal